Global Dry Eye Drugs Market Growth 2025-2031

Global Dry Eye Drugs Market Growth 2025-2031

The global Dry Eye Drugs market size is predicted to grow from US$ 10510 million in 2025 to US$ 21250 million in 2031; it is expected to grow at a CAGR of 12.4% from 2025 to 2031.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.

Global Dry Eye Drugs key players include Novartis AG, Valeant Pharmaceuticals, Allergan, Johnson & Johnson, Santen Pharma, etc. Global top five manufacturers hold a share about 75%.

North America is the largest market, with a share about 40%, followed by Asia-Pacific, and Europe, both have a share about 40 percent.

In terms of product, Artificial Tears is the largest segment, with a share over 85%. And in terms of application, the largest application is Hospital, followed by Drug Stores, Online Pharmacies.

LP Information, Inc. (LPI) ' newest research report, the “Dry Eye Drugs Industry Forecast” looks at past sales and reviews total world Dry Eye Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Dry Eye Drugs sales for 2025 through 2031. With Dry Eye Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Drugs industry.

This Insight Report provides a comprehensive analysis of the global Dry Eye Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dry Eye Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dry Eye Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Artificial Tears
Anti-inflammatory Drugs
Other

Segmentation by Application:
Hospital
Drug Stores
Online Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
Novartis AG
Bausch Health
Santen Pharma
Takeda
Johnson & Johnson
United Laboratories
Senju Pharmaceutical
Jianfeng Group
Eusan GMBH

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dry Eye Drugs market?

What factors are driving Dry Eye Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Dry Eye Drugs market opportunities vary by end market size?

How does Dry Eye Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.